{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:16:04Z","timestamp":1792592164315,"version":"4.5.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1097\/meg.0000000000000336","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T14:48:44Z","timestamp":1428072524000},"page":"631-637","source":"Crossref","is-referenced-by-count":23,"title":["Labour productivity losses caused by premature death associated with hepatitis C in Spain"],"prefix":"10.1097","volume":"27","author":[{"given":"Juan","family":"Oliva-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz M.","family":"Pe\u00f1a-Longobardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fern\u00e1ndez-Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Hidalgo-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrado M.","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20210207","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C.","volume":"44","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R3-3-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2009.01187.x","article-title":"New developments in the antiviral treatment of hepatitis C.","volume":"97","author":"de Bruijne","year":"2009","journal-title":"Vox Sang"},{"key":"R4-3-20210207","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2458-9-34","article-title":"HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.","volume":"9","author":"Miebertski","year":"2009","journal-title":"BMC Public Health"},{"key":"R6-3-20210207","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(89)91015-5","article-title":". Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.","volume":"2","author":"Bruix","year":"1989","journal-title":"Lancet"},{"key":"R7-3-20210207","first-page":"137","article-title":"Relationship between research funding in the Spanish National Health System and the burden of disease.","volume":"83","author":"Catala Lopez","year":"2009","journal-title":"Rev Esp Salud Publica"},{"key":"R9-3-20210207","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/MEG.0b013e328313139d","article-title":"Hepatitis C and hepatitis B-related mortality in Spain.","volume":"21","author":"Garcia-Fulgueiras","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R10-3-20210207","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.gastrohep.2009.01.181","article-title":"Cost-effectiveness of chronic hepatitis C treatment in Spain.","volume":"32","author":"Haj-Ali Saflo","year":"2009","journal-title":"Gastroenterol Hepatol"},{"key":"R11-3-20210207","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1365-2036.2007.03419.x","article-title":"Evaluating the cost of sustained virologic response in naive chronic hepatitis C patients treated a la carte.","volume":"26","author":"Buti","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-3-20210207","first-page":"291","article-title":"Budget impact analysis of the treatment of chronic hepatitis C in a hospital.","volume":"30","author":"Casado Gomez","year":"2006","journal-title":"Farm Hosp"},{"key":"R13-3-20210207","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1097\/MEG.0000000000000181","article-title":". Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.","volume":"26","author":"Stahmeyer","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R19-3-20210207","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1111\/j.1365-2893.2011.01467.x","article-title":"Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem.","volume":"18","author":"Garcrezea-Baziras","year":"2011","journal-title":"J Viral Hepat"},{"key":"R20-3-20210207","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"R21-3-20210207","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.20836","article-title":"Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland.","volume":"42","author":"Hutchinson","year":"2005","journal-title":"Hepatology"},{"key":"R22-3-20210207","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/gut.47.1.131","article-title":". Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.","volume":"47","author":"Degos","year":"2000","journal-title":"Gut"},{"key":"R23-3-20210207","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/01.ede.0000229155.05644.43","article-title":"An overview of methods for calculating the burden of disease due to specific risk factors.","volume":"17","author":"Steenland","year":"2006","journal-title":"Epidemiology"},{"key":"R24-3-20210207","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/oxfordjournals.aje.a121617","article-title":"Proportion of disease caused or prevented by a given exposure, trait or intervention.","volume":"99","author":"Miettinen","year":"1974","journal-title":"Am J Epidemiol"},{"key":"R25-3-20210207","first-page":"A14","article-title":"What does the population attributable fraction mean Prev Chronic D","volume":"4","author":"Levine","year":"2007","journal-title":"is"},{"key":"R27-3-20210207","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","article-title":"Cost-of-illness studies: a review of current methods.","volume":"24","author":"Akobundu","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"R28-3-20210207","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/eurheartj\/ehi733","article-title":"Economic burden of cardiovascular diseases in the enlarged European Union.","volume":"27","author":"Leal","year":"2006","journal-title":"Eur Heart J"},{"key":"R29-3-20210207","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10198-008-0135-0","article-title":"The socioeconomic costs of mental illness in Spain.","volume":"10","author":"Oliva-Moreno","year":"2009","journal-title":"Eur J Health Econ"},{"key":"R30-3-20210207","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11532230-000000000-00000","article-title":"Economic burden of multiple sclerosis: a systematic review of the literature.","volume":"28","author":"Naci","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"R31-3-20210207","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JAD-2011-102019","article-title":"Cost of dementia in the pre-enlargement countries of the European Union.","volume":"27","author":"Luengo-Fernandez","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"R32-3-20210207","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","article-title":"Economic burden of cancer across the European Union: a population-based cost analysis.","volume":"14","author":"Luengo-Fernandez","year":"2013","journal-title":"Lancet Oncol"},{"key":"R33-3-20210207","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMc1401726","article-title":"Daclatasvir plus sofosbuvir for HCV infection.","volume":"370","author":"Dhaliwal","year":"2014","journal-title":"N Engl J Med"},{"key":"R34-3-20210207","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":". Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R35-3-20210207","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":". ABT-450r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R36-3-20210207","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":". Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R37-3-20210207","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":". Sofosbuvir and ribavirin in HCV genotypes 2 and 3.","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R38-3-20210207","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for HCV infection.","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R39-3-20210207","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":". Retreatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R40-3-20210207","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":". Sofosbuvir for previously untreated chronic hepatitis C infection.","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R41-3-20210207","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":". Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"R42-3-20210207","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":". Treatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"R43-3-20210207","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":". Faldaprevir and deleobuvir for HCV genotype 1 infection.","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"R44-3-20210207","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":". Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R46-3-20210207","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges.","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"R47-3-20210207","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.hrtlng.2005.03.008","article-title":"Health-related quality of life in individuals with chronic obstructive pulmonary disease.","volume":"34","author":"Hu","year":"2005","journal-title":"Heart Lung"},{"key":"R50-3-20210207","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1192\/03-292","article-title":"Hidden costs of mental illness.","volume":"183","author":"Knapp","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R51-3-20210207","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.161.18.2231","article-title":"Costs of hepatitis C.","volume":"161","author":"Leigh","year":"2001","journal-title":"Arch Intern Med"},{"key":"R52-3-20210207","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-230X-13-16","article-title":"The burden of hepatitis C in Europe from the patients perspective: a survey in 5 countries.","volume":"13","author":"Vietri","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"R53-3-20210207","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2105\/AJPH.90.10.1562","article-title":"Estimating future hepatitis C morbidity, mortality, and costs in the United States.","volume":"90","author":"Wong","year":"2000","journal-title":"Am J Public Health"},{"key":"R55-3-20210207","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-8510(01)00159-2","article-title":"The cost of hepatitis C and the cost-effectiveness of its prevention.","volume":"58","author":"Shiell","year":"2001","journal-title":"Health Policy"},{"key":"R56-3-20210207","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.23726","article-title":"The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs.","volume":"52","author":"Su","year":"2010","journal-title":"Hepatology"},{"key":"R57-3-20210207","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MCG.0000000000000080","article-title":"Hepatitis C and work impairment: a review of current literature.","volume":"48","author":"Manne","year":"2014","journal-title":"J Clin Gastroenterol"},{"key":"R58-3-20210207","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/MEG.0b013e3283551dee","article-title":"The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes.","volume":"24","author":"daCosta DiBonaventura M, Yuan","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R59-3-20210207","doi-asserted-by":"crossref","first-page":"e86070","DOI":"10.1371\/journal.pone.0086070","article-title":"Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey.","volume":"9","author":"Dibonaventura","year":"2014","journal-title":"PLoS One"},{"key":"R60-3-20210207","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciu077","article-title":". Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010.","volume":"58","author":"Mahajan","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R62-3-20210207","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jmv.2091","article-title":"Community-based seroepidemiological survey of HCV infection in Catalonia, Spain.","volume":"65","author":"Domlerasz","year":"2001","journal-title":"J Med Virol"},{"key":"R63-3-20210207","first-page":"331","article-title":"Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain.","volume":"107","author":"Sacristll","year":"1996","journal-title":"Med Clin (Barc)"},{"key":"R64-3-20210207","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCG.0b013e3182485528","article-title":"Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life.","volume":"46","author":"Mohammad","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R65-3-20210207","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","article-title":"The friction cost method for measuring indirect costs of disease.","volume":"14","author":"Koopmanschap","year":"1995","journal-title":"J Health Econ"},{"issue":"Pt 1","key":"R67-3-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-199813010-00001","article-title":"How to calculate indirect costs in economic evaluations.","volume":"13","author":"Liljas","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"R68-3-20210207","first-page":"605","article-title":"Loss of labour productivity caused by disease and health problems: what is the magnitude of its effect on Spains economy Eur J Health E","volume":"13","author":"Oliva-Moreno","year":"2012","journal-title":"con"},{"key":"R69-3-20210207","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-013-0056-3","article-title":"Productivity costs in economic evaluations: past, present, future.","volume":"31","author":"Krol","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"R70-3-20210207","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.socscimed.2010.10.026","article-title":"Measuring and valuing productivity loss due to poor health: a critical review.","volume":"72","author":"Zhang","year":"2011","journal-title":"Soc Sci Med"},{"key":"R71-3-20210207","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hec.1795","article-title":"Productivity costs revisited: toward a new US policy.","volume":"21","author":"Nyman","year":"2012","journal-title":"Health Econ"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000000336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:50:56Z","timestamp":1620964256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201506000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000000336","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}